|
1
|
Kondo K: Therapy for thymic epithelial
tumors. Gen Thorac Cardiovasc Surg. 62:468–474. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Travis WD, Brambilla E, Burke AP, Marx A
and Nicholson AG: WHO classification of tumours of the lung,
pleura, thymus and heart. World Health Organization classification
of tumours. Bosman FT, Jaffe ES, Lakhani SR and Ohgaki H: 4th
edition. IARC Press; Lyon: pp. 183–243. 2015
|
|
3
|
Shimosato Y, Mukai K and Matsuno Y: Tumors
of the mediastinum. AFIP Atlas of tumor pathology, Series 4. Armed
Forces Institute of Pathology Washington, DC: 2010
|
|
4
|
Wang Y, Thomas A, Lau C, Rajan A, Zhu Y,
Killian JK, Petrini I, Pham T, Morrow B, Zhong X, et al: Mutations
of epigenetic regulatory genes are common in thymic carcinomas. Sci
Rep. 4:73362014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Radovich M, Pickering CR, Felau I, Ha G,
Zhang H, Jo H, Hoadley KA, Anur P, Zhang J, McLellan M, et al: The
integrated genomic landscape of thymic epithelial tumors. Cancer
Cell. 33:244–258.e10. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Petrini I, Meltzer PS, Kim IK, Lucchi M,
Park KS, Fontanini G, Gao J, Zucali PA, Calabrese F, Favaretto A,
et al: A specific missense mutation in GTF2I occurs at high
frequency in thymic epithelial tumors. Nat Genet. 46:844–849. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hirose Y, Kondo K, Takizawa H, Nagao T,
Nakagawa Y, Fujino H, Taba H, Kenzaki K, Sakiyama S and Tangoku A:
Aberrant methylation of tumour-related genes in thymic epithelial
tumours. Lung Cancer. 64:155–159. 2009. View Article : Google Scholar
|
|
8
|
Mokhtar M, Kondo K, Namura T, Ali AH,
Fujita Y, Takai C, Takizawa H, Nakagawa Y, Toba H, Kajiura K, et
al: Methylation and expression profiles of MGMT gene in thymic
epithelial tumors. Lung Cancer. 83:279–287. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Detterbeck FC, Nicholson AG, Kondo K, Van
Schil P and Moran C: The Masaoka-Koga stage classification for
thymic malignancies: Clarification and definition of terms. J
Thorac Oncol. 6(7 Suppl 3): S1710–S1716. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kajiura K, Masuda K, Naruto T, Kohmoto T,
Watanabe M, Tsuboi M, Takizawa H, Kondo K, Tangoku A and Imoto I:
Frequent silencing of the candidate tumor suppressor TRIM58 by
promoter methylation in early-stage lung adenocarcinoma.
Oncotarget. 8:2890–2905. 2017. View Article : Google Scholar :
|
|
11
|
Moskalev EA, Jandaghi P, Fallah M,
Manoochehri M, Botla SK, Kolychev OV, Nikitin EA, Bubnov VV, von
Knebel Doeberitz M, Strobel O, et al: GHSR DNA hypermethylation is
a common epigenetic alteration of high diagnostic value in a broad
spectrum of cancers. Oncotarget. 6:4418–4427. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pal J, Patil V, Mondal B, Shukla S, Hegde
AS, Arivazhagan A, Santosh V and Somasundaram K: Epigenetically
silenced GNG4 inhibits SDF1α/CXCR4 signaling in mesenchymal
glioblastoma. Genes Cancer. 7:136–147. 2016.PubMed/NCBI
|
|
13
|
Marzese DM, Scolyer RA, Huynh JL, Huang
SK, Hirose H, Chong KK, Kiyohara E, Wang J, Kawas NP, Donovan NC,
et al: Epigenome-wide DNA methylation landscape of melanoma
progression to brain metastasis reveals aberrations on homeobox D
cluster associated with prognosis. Hum Mol Genet. 23:226–238. 2014.
View Article : Google Scholar
|
|
14
|
Misawa K, Mochizuki D, Imai A, Misawa Y,
Endo S, Mima M, Kawasaki H, Carey TE and Kanazawa T: Epigenetic
silencing of SALL3 is an independent predictor of poor survival in
head and neck cancer. Clin Epigenetics. 9:642017. View Article : Google Scholar :
|
|
15
|
Kojima M, Hosoda H, Date Y, Nakazato M,
Matsuo H and Kangawa K: Ghrelin is a growth-hormone-releasing
acylated peptide from stomach. Nature. 402:656–660. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Howard AD, Feighner SD, Cully DF, Arena
JP, Liberator PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC,
Anderson J, et al: A receptor in pituitary and hypothalamus that
functions in growth hormone release. Science. 273:974–977. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lin TC and Hsiao M: Ghrelin and cancer
progression. Biochim Biophys Acta Rev Cancer. 1868:51–57. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jandaghi P, Hoheisel JD and Riazalhosseini
Y: GHSR hyper-methylation: A promising pan-cancer marker. Cell
Cycle. 14:689–690. 2015. View Article : Google Scholar :
|
|
19
|
Clapham DE and Neer EJ: G protein beta
gamma subunits. Annu Rev Pharmacol Toxicol. 37:167–203. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Maina EN, Morris MR, Zatyka M, Raval RR,
Banks RE, Richards FM, Johnson CM and Maher ER: Identification of
novel VHL target genes and relationship to hypoxic response
pathways. Oncogene. 24:4549–4558. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
McGinnis W and Krumlauf R: Homeobox genes
and axial patterning. Cell. 68:283–302. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shah N and Sukumar S: The Hox genes and
their roles in oncogenesis. Nat Rev Cancer. 10:361–371. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tabuse M, Ohta S, Ohashi Y, Fukaya R,
Misawa A, Yoshida K, Kawase T, Saya H, Thirant C, Chneiweiss H, et
al: Functional analysis of HOXD9 in human gliomas and glioma cancer
stem cells. Mol Cancer. 10:602011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lv X, Li L, Lv L, Qu X, Jin S, Li K, Deng
X, Cheng L, He H and Dong L: HOXD9 promotes epithelial-mesenchymal
transition and cancer metastasis by ZEB1 regulation in
hepatocellular carcinoma. J Exp Clin Cancer Res. 34:1332015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kohlhase J, Hausmann S, Stojmenovic G,
Dixkens C, Bink K, Schulz-Schaeffer W, Altmann M and Engel W:
SALL3, a new member of the human spalt-like gene family, maps to
18q23. Genomics. 62:216–222. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Strathdee G, Sutherland R, Jonsson JJ,
Sataloff R, Kohonen-Corish M, Grady D and Overhauser J: Molecular
characterization of patients with 18q23 deletions. Am J Hum Genet.
60:860–868. 1997.PubMed/NCBI
|
|
27
|
Yang XX, Sun JZ, Li FX, Wu YS, Du HY, Zhu
W, Li XH and Li M: Aberrant methylation and downregulation of sall3
in human hepatocellular carcinoma. World J Gastroenterol.
18:2719–2726. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shikauchi Y, Saiura A, Kubo T, Niwa Y,
Yamamoto J, Murase Y and Yoshikawa H: SALL3 interacts with DNMT3A
and shows the ability to inhibit CpG island methylation in
hepatocellular carcinoma. Mol Cell Biol. 29:1944–1958. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wei X, Zhang S, Cao D, Zhao M, Zhang Q,
Zhao J, Yang T, Pei M, Wang L, Li Y and Yang X: Aberrant
hypermethylation of SALL3 with HPV involvement contributes to the
carcinogenesis of cervical cancer. PLoS One. 10:e01457002015.
View Article : Google Scholar : PubMed/NCBI
|
